Sun Pharmaceutical Industries Ltd Update on US FDA Inspection at Mohali Facility

The US FDA conducted an inspection of Mohali manufacturing facility (Punjab, India) of Sun Pharmaceutical Industries Limited ("the Company") from August 3, 2022 to August 12, 2022. At the conclusion of the inspection, the US FDA issued a Form-483, with 6 observations. The Company is preparing the response to the observations, which will be submitted to US FDA within the stipulated timeline.

The Company is committed to address these observations promptly. The Company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 913.40 as compared to the previous close of Rs. 920.00. The total number of shares traded during the day was 27792 in over 1299 trades.

The stock hit an intraday high of Rs. 924.90 and intraday low of 907.50. The net turnover during the day was Rs. 25364014.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 Mohali USFDA Inspection Form483 6Observations